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S U M M A R Y
Objectives: The objectives of this studywere to assess the prevalence and factors associatedwith hepatitis
C virus (HCV) infection in human immunodeﬁciency virus (HIV)-infected and –uninfected Thai pregnant
women and the rate of HCV transmission to their infants.
Patients and methods: Study subjects included 1435 HIV-infected pregnant women and their infants,
enrolled in a perinatal HIV prevention trial, and a control group of 448 HIV-uninfected pregnant women.
Women were screened for HCV antibodies with an enzyme immunoassay. Positive results were
conﬁrmed by recombinant immunoblot and HCV RNA quantiﬁcation. Infants were tested for HCV
antibodies at 18 months or for HCV RNA at between 6 weeks and 6 months.
Results: Of the HIV-infected women, 2.9% were HCV-infected compared to 0.5% of HIV-uninfected
women (p = 0.001). Only history of intravenous drug use was associated with HCV infection in HIV-
infected women. Ten percent of infants born to co-infected mothers acquired HCV. The risk of
transmission was associated with a high maternal HCV RNA (p = 0.012), but not with HIV-1 load or CD4
count.
Conclusions: Acquisition of HCV through intravenous drug use partially explains the higher rate of HCV
infection in HIV-infected Thai women than in HIV-uninfected controls. Perinatal transmission occurred
in 10% of infants of HIV–HCV-co-infected mothers and was associated with high maternal HCV RNA.
 2009 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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The prevalence of hepatitis C virus (HCV) infection worldwide is
estimated to be around 2%, representing about 123 million infected
persons.1–3 In 2004 the estimated prevalences of HCV in the six
World Health Organization (WHO) regions were 5.0% in the Eastern
Mediterranean, 3.0% in Africa, 2.1% in the Western Paciﬁc, 1.7% in
Europe, 1.3% in the American region, and 1.2% in Southeast Asia.2§ This work was presented in part at the 5th Dominique Dormont International
Conference, Paris, France, March 26–28, 2009.
* Corresponding author. Tel.: +66 53 894 431; fax: +66 53 894 220.
E-mail address: nicole@phpt.org (N. Ngo-Giang-Huong).
1201-9712/$36.00 – see front matter  2009 International Society for Infectious Disea
doi:10.1016/j.ijid.2009.09.002Signiﬁcant differences exist between developed and developing
countries regarding major risk factors for HCV infection. In
developed countries, with the discovery of hepatitis C virus in
1989 and the introduction of effective screening of donors, infected
blood transfusions were replaced by percutaneous exposure
through injection drug use as the primary mode of transmission
of HCV infection. In the developingworld, unsafemedical injections
and, in someareas, inadequately screenedblood transfusions are the
predominantmodes ofHCV infection.3,4 Sexual transmission ofHCV
is less frequent and has been associated only with high-risk sexual
behavior.5–9 As a result of shared risk factors, HCV is more common
in individuals infected with the human immunodeﬁciency virus
(HIV) than in the general population, particularly among injectingses. Published by Elsevier Ltd. All rights reserved.
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little is known about the mechanisms of HCV transmission in non-
intravenous drug-using (non-IVDU) populations.
The acquisition of HCV infection through perinatal transmission
is estimated to occur in about 5% of infants born to HCV-infected
mothers.15–20 A highmaternal HCV RNA level has been found to be
associated with perinatal transmission.15,16,18,21–26 Most studies
have reported a higher risk of HCV transmission to infants born to
HIV-co-infectedmothers,27–32 but themechanismof this increased
risk is unclear. Long duration of membrane rupture24,29 and female
sex of infants have also been associated with vertical transmission
of HCV.33 Breastfeeding does not appear to pose an additional
risk,22,34 and, while there is some disagreement,33,34 cesarean
section does not seem to play a role in protection.33,35
In Thailand, where HIV prevalence among pregnant women
attending public antenatal care facilities was 1.0% in 2005,36 data
on the prevalence of HCV have been limited to a single study in the
Bangkok area. In this study conducted between 1992 and 2004, a
prevalence of 0.3% in HIV-uninfected women and 3.8% in HIV-
infected women was shown. An increase in prevalence was found
over this time period.37
The objectives of our study were to estimate the prevalence of
HCV infection in a large population of HIV-infected pregnant
women and a control group of HIV-uninfected pregnant women in
Thailand, and to study risk factors associated with maternal HCV
infection. We also describe the risk of perinatal HCV transmission
from HIV–HCV-co-infected mothers to their infants, and risk
factors associated with HCV transmission from mother to child.
2. Materials and methods
2.1. Population
Between June 1997 and December 1999, 36 738 pregnant
womenwere tested for HIV-1 infection at 27 hospitals in Thailand,Fig. 1. HCV infection status of HIV-infected and HIV-uninfected pregnant women and HC
HIV–HCV-co-infected women with HCV viremia, one woman delivered twins. Two childand 1435 infected women were enrolled into a clinical trial aimed
to deﬁne the optimal duration of zidovudine administration for the
prevention of perinatal transmission of HIV (Perinatal HIV
Prevention Trial-1 or PHPT-1, ClinicalTrials.gov NCT00386230).38
HIV-infected women were instructed not to breastfeed their
infants. A control group of 448 HIV-uninfected pregnant women
was randomly selected at the same enrolment sites following a
ratio of 1:3.
Age, marital status, parity, history of intravenous (IV) drug use,
history of sexually transmitted diseases, and history of transfusion
and hospitalization were recorded at the ﬁrst antenatal visit,
before 28 weeks of gestation (median 26 weeks). Blood samples
were obtained from infants born to HIV-infected mothers at birth,
6 weeks, 4, 6, 9, 12, 15 and 18 months of age. Blood samples from
HIV-uninfected women and their infants were not available after
screening because they were not followed in this trial.
2.2. Virological and other biological evaluations
Methods used for HIV diagnosis in mothers and infants in this
cohortwere as previously published.38 To determineHCV infection
status in mothers, HCV antibodies were assessed at a median 26
weeks of gestation using a third generation enzyme-linked
immunosorbent assay (EIA; Murex anti-HCV kit, version 4.0,
Abbott Murex, Kyalami, South Africa). Women testing HCV EIA-
negative were considered HCV-uninfected. Samples from women
testing EIA-positive were retested for HCV RNA quantiﬁcation by
PCR (COBAS Amplicor HCV monitorTM test, version 2.0, Roche
Molecular Systems, Inc., Branchburg, NJ, USA) and by recombinant
immunoblot assay (Bioblot HCV, Biokit S.A., Spain). Women with
an undetectable HCV RNA level and positive immunoblot were
considered to have been HCV-infected but to have recovered.
Women with a detectable HCV RNA level were considered to have
active HCV infection. If their HCV RNA was undetectable and
immunoblot was negative, women were considered to be HCV-V infection status for children born to HIV–HCV-co-infected women. Among the 30
ren could not be assessed for HCV infection since no blood samples were available.
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band by immunoblot were considered to have an indeterminate
HCV status.39
To determine the HCV infection status in children, the EIA was
performed on samples drawn at 18 months of age and the same
algorithm was used. If the 18 months of age sample was missing,
HCVRNAwas quantiﬁed in samples drawn at between 6weeks and
6 months of age. Infants with detectable HCV RNA at any time
during this age interval were considered positive.40
Plasma HCV RNA and HIV-1 RNA were quantitated using the
Cobas Amplicor HCV Monitor test v. 2.0 and the Cobas Amplicor
HIVMonitor test v. 1.5, respectively (RocheMolecular Systems, Inc,
Branchburg, New Jersey, USA). The lower limit of RNA detection
was 600 IU/ml for HCV and 400 copies/ml for HIV. HCV genotype
was determined using a line probe assay (Versant1 HCV genotype
2.0, Siemens Medical Solutions Diagnostics, Belgium) according to
the manufacturer’s instructions.
Women had CD4 enumeration and serum alanine aminotrans-
ferase (ALT) measurement during pregnancy and children a serum
ALT measurement at birth.
2.3. Data analysis
The baseline characteristics of HIV-infected and –uninfected
pregnant women were analyzed according to their HCV status. We
used the Fisher’s exact test to compare distributions of categorical
data and the Wilcoxon rank-sum test for continuous variables.
Statistical analyses were performed using Stata 10.1 (StataCorp LP,
Texas, USA).
2.4. Ethical considerations
Written informed consent for this study was provided by
women on entry to the parent study, PHPT-1, and the protocol was
approved by the ethics committees at the Harvard School of Public
Health and the Thai Ministry of Public Health.
3. Results
3.1. Prevalence and risk factors of HCV infection in pregnant women
Among the 69 HIV-infected and ﬁve HIV-uninfected women
with a positive EIA, HCV seropositivity was conﬁrmed by HCV RNA
and/or recombinant immunoblot in 42 and two women, respec-
tively (Fig. 1). Thirteen women had an indeterminate immunoblot
and undetectable HCV RNA and were thus considered HCV
indeterminate.39 The prevalence of HCV was 2.9% (42/1435)
among HIV-1-infected women compared to 0.5% (2/448) among
HIV-uninfected pregnant women (p = 0.001) (Fig. 1). The women’sTable 1
Baseline characteristics according to HCV status in HIV-infected cases and controls
HIV-infected
HCV-infected HCV-uni
n 42 1393
Age, median years (IQR) 25.7 (21.6–28.8) 24.8 (21.
Education at least primary school 11/41 (27%) 454/1378
Married or cohabitating 40/40 (100%) 1346/134
Primiparity 21/42 (50%) 770/1367
History of hospitalization(s) since 1989 13/41 (32%) 376/1306
History of blood transfusion(s) since 1989 2/41 (5%) 38/1301
History of intravenous drug use 3/41 (7%) 6/1306 (
History of sexually transmitted diseases during
the past 3 months
3/41 (7%) 69/1299
HIV RNA log10/ml, median (IQR) 3.85 (3.27–4.46) 3.92 (3.3
CD4 count/mm3, median (IQR) 400 (240–534) 360 (240
HCV, hepatitis C virus; HIV, human immunodeﬁciency virus; IQR, interquartile range;characteristics are presented in Table 1. Among HIV–HCV-co-
infectedwomen, 7% (3/41) self-reported a history of IV drug use vs.
0.5% (6/1306) of women infected with HIV only (p = 0.002). The
other baseline characteristics studied were not signiﬁcantly
different between these two groups.
There was a disparity in the distribution of HCV prevalence in
HIV-infected women according to the region and the type of
regional economic activity, with higher prevalence (that is at or
above 2.9%, the median for the entire country) foundmore often in
regions with predominant commercial or industrial activities. In
the Bangkok area and the east, the prevalence of HCV infectionwas
found at or above the median at ﬁve of six sites (median 3.8%;
range 1.5–7.9%) and six of eight sites (median 3.3%; range 0–5.9%),
respectively. In the north, where economic activity is predomi-
nantly agricultural, theHCV prevalencewas at or above themedian
in only four of 12 sites (median 2.3%; range 0–6.9%). There was no
HCV infection case in the single site located in the south.
Among the 42 HIV–HCV-co-infected women, 71% had a
detectable HCV viremia (3.61–6.12 log10 IU/ml). However, only
three co-infected women had elevated serum ALT levels, and these
abnormalities were modest (64, 66, and 75 IU).
Among HIV-infected women, the median HIV RNA was not
different between HCV-infected women (n = 42) and HCV-unin-
fected women (n = 1393); 3.85 log10 copies/ml (95% conﬁdence
interval (CI) 3.49–4.28) vs. 3.92 (95% CI 3.86–3.99) (p = 0.46)
suggesting that HCV had no impact on HIV replication. Moreover,
in HCV-viremic women the level of HCV RNA was not signiﬁcantly
associated with either HIV RNA (p = 0.94) or CD4 (p = 0.54).
HCV genotype could be determined for the 32 women with
detectable HCV RNA. Genotype 3a was the most prevalent
genotype, accounting for 38% of HCV infection. Genotype 1a was
identiﬁed in six women (19%) and genotype 1b in seven women
(22%). Genotypes 6c to 6i were identiﬁed in six women (19%).
3.2. Perinatal transmission of HCV
HCV status could be assessed in 41 infants (Fig. 1); one of the 42
HIV–HCV-co-infected women was lost to follow-up before
delivery, one child died shortly after birth, and one mother
delivered twins. Twenty-eight infants had an 18-month blood
sample available and were tested for HCV antibodies. For thirteen
children, HCV RNAwas quantitated in plasma obtained at between
6 weeks and 6 months. Two children were positive for HCV
antibody at 18 months of age and two others had measurable HCV
RNA, one at 6 weeks of age and the other at 6 months of age.
Among HIV–HCV-co-infected women, the risk of perinatal HCV
transmission was 10% (4/40) (95% CI 3– 20%) overall, or 13% (4/29)
(95% CI 4–27%) when restricted to mothers with HCV viremia. HCV
RNA was found in the plasma of all four children, with titersControls
nfected p-Value HCV-infected HCV-uninfected p-Value
2 446
9–28.3) 0.68 18.5 and 25.3 25.9 (21.6–30.7) 0.28
(33%) 0.41 2/2 163/441 (37%) 0.066
8 (99.9%) 1.00 2/2 441/441 1.00
(56%) 0.43 1/2 (50%) 266/439 (61%) 1.00
(29%) 0.73 1/2 (50%) 103/392 (26%) 0.46
(3%) 0.35 0/2 7/392 (2%) 1.00
0.5%) 0.002 0/2 1/392 (0.3%) 1.00
(5%) 0.48 0/2 3/392 (1%) 1.00
4–4.48) 0.94 ND
–510) 0.54 ND
ND, not determined .
Fig. 2. Distribution of plasma HCV RNA concentrations (panel a) and CD4 lymphocyte counts (panel b) among HIV–HCV-co-infected mothers who transmitted (transmitters)
or did not transmit (non-transmitters) HCV to their infants. Middle horizontal lines indicate medians.
N. Ngo-Giang-Huong et al. / International Journal of Infectious Diseases 14 (2010) e602–e607 e605ranging from 4.8 to 6 log10 HCV IU/ml. Serum ALT results were
available at birth for three HCV-infected babies and were normal.
3.3. Risk factors for perinatal HCV transmission
Perinatal HCV transmission was associated with a high
maternal HCV viral load (p = 0.012): all HCV transmitting mothers
had an HCV viral load above 5.5 log10 IU/ml (Fig. 2a). Perinatal HCV
transmission was not associated with maternal HIV viral load or
absolute CD4 lymphocyte count (p = 0.365; Fig. 2b). Delivery of the
four HCV-infected children occurred vaginally with a time from
labor onset to delivery ranging from 5.5 to 7.9 h. Among the 36
women who did not transmit HCV infection, 31 women delivered
vaginally and six delivered through cesarean section, including
three prior to onset of labor and rupture of membranes. The
childrenwere infectedwith different HCV genotypes (1a, 1b, 3, and
3a).
3.4. Relationship between HIV and HCV perinatal transmission
Two of 39 HCV-co-infected mothers (5.1%) transmitted HIV to
their children compared to 95 of 1342 (7.1%) HIV-only-infected
mothers (p = 0.48). There were no cases of co-transmission.
4. Discussion
Our study showed that the prevalence of HCV infection was
signiﬁcantly higher in HIV-infected pregnant women than in HIV-
uninfected pregnant women in Thailand, 2.9% vs. 0.5%. A history of
IV drug use was the only risk factor signiﬁcantly associated with
HCV infection among the group of HIV-infected pregnant women.
Only 0.7% of HIV-infected pregnant women self-reported a history
of IV drug use – 7% (4/41) of HCV-infected vs. 0.5% (6/1306) of HCV-
uninfected women; this suggests that other risk factors for HCV
infection were present that were not identiﬁed. Although some
womenmay not have reported prior IV drug use because of fears of
disclosure, it is unlikely that this alone explains all HCV infections
found in this population. In a study conducted among pregnantwomen in the Bangkok area, IV drug use in women’s sexual
partners was found to be associated with the risk of HCV infection.
We could not evaluate this factor since women were not
speciﬁcally asked about the IV drug use of their sexual partners.
We observed prevalences of HCV in the two groups of women
similar to those described in the Bangkok study, with comparable
ranges of HIV RNA and CD4 counts.37 However, because we
included women from several regions of Thailand we were able to
show a trend towards higher rates of HCV infection inwomen from
industrial areas around Bangkok and in the east.
The 0.5% rate of HCV infection among HIV-uninfected women
was lower than the 2.8% rate of HCV reported among persons
screened as potential blood donors in northern Thailand around
the same period.41 Other studies in volunteer blood donors in
Thailand have reported rates of HCV prevalence of between 1.3%
and 5.6%.42–44 Because it was randomly selected, our sample of
HIV-uninfected women was likely unbiased, and the low preva-
lence observed could be attributable to the higher speciﬁcity of our
HCV serology screening algorithm, the sex of our study subjects,
their age, and the lack of speciﬁc risk factors for HCV infection.
Indeed, the prevalence of HCV has been shown to be higher in
males than in females,43–45 and to increase with age43 and with
risk factors such as a history of IVDU,10–14,44 blood transfusion3,4,44
or a high-risk sexual behavior.5–9,44
Among HIV-infected women, the rate of perinatal transmission
of HCV was associated with a high maternal HCV RNA level,
consistent with ﬁndings reported in studies conducted in other
settings.15,16,18,21–26 Transmission of HCV from mother to infant
occurred in 10% of co-infected women overall. While transmission
was not observed in the women with undetectable viremia, it was
seen in 13% of those with measurable HCV viremia, and only in
womenwith the highest viral load, above 5.5 log IU/ml. These rates
are higher than the point estimate found in the only previous study
of HIV–HCV co-infection and vertical transmission in Thailand, and
closer to those reported in European and American studies. The
rate of perinatal transmission of HIVwas not different in HIV–HCV-
co-infected women and in women with HIV infection alone. It has
been proposed that the higher rate of vertical HCV transmission in
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in mothers as a result of immunosuppression secondary to HIV
infection,46 and one large study from the USA has shown an inverse
correlation between maternal percent CD4 and HCV transmis-
sion.18 On the other hand, this study did not report absolute CD4
concentrations.We did not observe any association between either
maternal plasmaHCV RNA level or perinatal HCV transmission and
maternal absolute CD4 concentration, nor was there a correlation
between HIV and HCV viral loads.
In conclusion, we have shown in this ﬁrst nationwide study of
HCV infection in Thai pregnant women that the prevalence of HCV
infection among HIV-uninfected women was very low (0.5%), in
contrast to a moderately high prevalence in HIV-infected women
(2.9%). Only 7% of HIV–HCV-infected women self-reported a
history of IV drug use, while 38% were infected with the genotype
3a, known to be associated with IV drug use in Thailand. Although
other risk factors for HCV likely remain unidentiﬁed, some of
which may be common with risk factors for HIV, IV drug use was
likely underreported, highlighting the profound stigma attached to
this in the female population. Perinatal transmission of HCV was
signiﬁcantly associated with a high maternal HCV RNA (p = 0.012).
Surprisingly, HCV infection did not appear to be associated with
the level of maternal HIV replication or the perinatal transmission
of HIV.
This study conﬁrms and extends data on the prevalence and
risks factors of HCV infection in pregnant women in Thailand, as
well as rates and risk factors of mother-to-child transmission in
HIV–HCV-co-infected women.
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